Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 27, 2016

View Archived Issues

Pfizer discloses vanin-1 inhibitors

A-000830 is a promising novel small-molecule inhibitor of ecto-nucleotidase CD73

HTL-001 is highly cytotoxic to prostate and breast cancer cells in vitro and in vivo

Ono gains access to Ligand Pharmaceuticals' OmniAb platform

Bantam Pharmaceutical patents mRNA translation initiation inhibitors

Lead Pharma Cel Models and Sanofi disclose RORgamma modulators

GlaxoSmithKline and University of Dundee describe antiparasitic agents

Genticel and Genkyotex sign contribution agreement

First patient enrolled in LTX-315 anti-PD-1 combination study

RespireRx Pharmaceuticals announces positive results from phase IIb PACE study

RO-689921 is well tolerated in patients with solid tumors

Neothetics initiates phase II trial of LIPO-202 for the reduction of submental subcutaneous fat

Strongbridge Biopharma acquires U.S. rights to Keveyis from Taro

First patient enrolled in BioHaven's phase IIb/III study of BHV-4157

FDA grants approval to Spinraza for treatment of spinal muscular atrophy

FDA accepts betrixaban NDA for priority review, EMA validates MAA

Pluristem and NYBC to collaborate in developing PLX-R18 cell therapy

Tokai Pharmaceuticals and Otic Pharma enter definitive share purchase agreement

Biocartis announces RAS biomarker testing collaboration with Amgen in Europe

Phase IIb data support advancement of linaclotide colonic release-1 in IBS-C

Dipexium and PLx Pharma enter merger agreement

Synergy Pharmaceuticals reports topline results of second pivotal study of plecanatide in IBS-C

TiGenix submits responses to EMA regarding Cx-601 MAA

MSD seeks approval of additional indication for Keytruda in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...